ScreenCell® is reshaping liquid biopsy and modern oncology as a pioneer in capturing circulating tumor cells (CTCs) with its performant and cost-effective filtration devices.
Explore over 70 scientific articles authored by our customers and partners that showcase the effectiveness of our technology
Over 70,000 filtration units used in fundamental and clinical research projects worldwide.
Trace back over 10 years of experience, know-how and innovation.
+90%
circulating tumor cells recovery rate.
Through its innovative filtration devices, CYTO and MB, ScreenCell® has transformed the isolation and enrichment of circulating tumor cells (CTCs) in liquid biopsy, delivering an unparalleled blend of simplicity, precision, and efficiency.
Explore the full range of ScreenCell® kits, each specifically designed to meet the diverse needs of liquid biopsy applications.
Blood sample
< 3 days
or
Cells fixed detached
from the isolation support for analysis in suspension or on slide
Blood sample
< 4 hours
or
Cells fixed detached
from the isolation support for analysis in suspension or on slide
Blood sample
< 4 hours
Living cells detached
from the isolation support for suspension analysis
Discover the diverse range of applications offered by ScreenCell® technology, focusing on three key areas : cytology, molecular biology and cell culture.
Stay updated with the latest news and events from ScreenCell® through our articles.
